Agreement signed with major cancer center

RNS Number : 2088G

Oncimmune Holdings PLC

23 July 2021

 

23 July 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Agreement signed with major cancer center to profile patients in immuno-oncology trial

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute ("Dana-Farber") in Boston, Massachusetts. Dana-Farber, a clinical affiliate and research institute of Harvard Medical School, is a world-leading cancer research organisation and one of America's top-rated cancer hospitals with more than 1,100 therapeutic and non therapeutic clinical trials in progress.

Under this agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTag^TM, to identify autoantibodies that can be predictive of patient response or associated with resistance to checkpoint inhibitors ("CPIs") and chemotherapy used in Dana-Farber led studies or therapy using atezolizumab, nivolumab, pembrolizumab, durvalumab and cisplatin-based chemotherapy. In addition, SeroTag will be used for identifying autoantibodies that can be predictive of immune-related adverse events ("irAEs") in response treatment. The project is scheduled to complete by the end of 2021.

SeroTag is a high-throughput, multiplex, discovery technology based on Oncimmune's in-house protein library, one of the largest in the world, with a unique, ever-growing repository of disease data for indications such as autoimmune and infectious diseases as well as cancer. The proprietary SeroTag immuno-oncology discovery array is based on autoantibody profiling studies in autoimmune diseases and other cancer types, and comprises known and proprietary antigens linked to a number of cancers, autoimmune and infectious diseases.

Dr Adam M Hill, CEO of Oncimmune said:  "We are delighted to be partnering with such a prestigious organisation as Dana-Farber on the use of multiple CPI assets in this important oncology trial and leveraging the power of our autoantibody biomarker profiling technology.

"As autoantibodies continue to be recognised as a key biomarker class that aid in the understanding of interactions between cancer and the immune system, the ImmunoINSIGHTS platform is becoming increasingly instrumental in studies for a wide range of cancer indications and therapy classes." 

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

[phone]

Singer Capital Markets (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Nigel Birks

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners .

Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, and has a discovery research centre in Dortmund, Germany.

For more information, visit  www.oncimmune.com

What is ImmunoINSIGHTS?

The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

What is SeroTag?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag analyses autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAID disease-specific stratification panels-precision medicine tools which are enabling patient and disease stratification and support therapeutic development.

 

END

 

 

AGRDKBBDFBKDBOB